Transfering the IP from the inventor to the bench with Battelle Research Institute as the development partner. Continue to believe in the positive outcomes when cancer is detected early. StrandSmart is marrying nanotechnologies with cancer biology to make a difference in early detection of solid cancers.

LaurelWey Consulting, LLC is my business specializing in CLIA laboratories and molecular diagnostics. Product Development and commercial and payor strategies.

World wide commercialization of the CancerPlex line of NGS tests. Built a US sales force, developed distributors X-US and interfaced with R+D for new product plans. Involved in the bioinformatics pipeline strategy.

World wide commercialization of the MyCare line of chemotherapy tests.

About RPSFounded in 2004, Rapid Pathogen Screening, Inc. (RPS) is a leading developer, manufacturer and marketer of rapid, easy-to-use, point-of-care diagnostic tests. The company’s revolutionary, patented Direct Sampling Micro-Filtration (DSMF) technology and patent-pending Direct Multi-Planar Chromafiltography (DMC) technology allow for the current and future development of tests to confirm patients with infectious diseases and agents, inflammatory conditions, and asymptomatic exposure to chemical warfare and bio-terrorism agents. RPS tests have superior sensitivity and specificity and can be easily performed by a clinician’s staff without extensive training or additional equipment.

Responsible for the diagnostics unit of Hologic, Inc. Businesses were formerly known as Cytyc and Third Wave.

Increase revenue and lowered costs to get to break even. M+A activity and achieved a positive coverage determination ( LCD) for the PancraGEN test.

General Manager of the Veridex, LLC unit, molecular and cellular diagnostics.

My responsibilities included clinical development, reimbursement and medical affairs.